| 摘要 |
The present invention is a drug delivery carrier comprising: (a) a biocompatible polymer and (b) a hydrophobic group conjugated to said polymer. The invention is used for adsorption of synthetic drugs having very low solubility in water, and it regulates discharge rate of adsorbed drugs by regulating a proportion of hydrophobic groups conjugated to the polymeric material. The present invention provides broad-spectrum platform technology applicable to new hydrophobic synthetic drugs to be developed in the future as well as drugs that face difficulties in development due to low bioavailability. The invention will provide therapeutic convenience by combining sustained-release characteristics with the ability for adsorption of a hydrophobic drug having low bioavailability. The invention can also be applied to protein therapeutics. Using first-generation protein drugs based on expired patents which cover daily, every two or three days administration, the present invention improves convenience by allowing second-generation injection formulations that are administered once a week or one or two times a month. "First-generation protein" refers to a bio-medicine based on a natural protein prepared by gene recombination technique and "second-generation protein" refers to a bio-pharmaceutical improvement of a first-generation protein through formulation techniques or modification of molecular structure for increasing half-life or extending treatment period through sustained release. The objects of the present invention are achieved by using first-generation or second-generation protein drugs through a simple mixture or regulation of drug delivery carrier adsorption, unlike known techniques that require protein modification or introduction of a special molecular structure. Applying the present invention will shorten development time of next-generation drugs, and this system will effectively contribute to increasing use of hydrophobic synthetic drugs. Ultimately, the present invention will be useful for development of competitive new medicines such as sustained-release proteins and synthetic pharmaceuticals. |
